
Jaguar Health, Inc. ("Jaguar") (Nasdaq: JAGX) and its family company Napo Pharma ("Napo") is focused on developing innovative solutions sustainably derived from plants from rainforest areas for people and animals with GI issues.
Nasdaq: JAGX
Jaguar Health - Investors & News: https://jaguarhealth.gcs-web.com/
Nasdaq Profile: https://www.nasdaq.com/market-activity/stocks/jagx
Headquarters: San Francisco, California
TALK TO MANAGEMENT
Jaguar Health, Inc. is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
Investor Presentation


To download the investor presentation, please fill out the form below.
Stock Chart (Intraday)
Stock Chart (Historical)
Stock Detail
Financial Summary

In 2022, Jaguar reported total revenues of $12 million, a significant 175.8% increase compared to revenues of $4.3 million in 2021. The revenue growth was primarily driven by increased sales of a new product. This growth reflects the company's transition from a wholesaler distribution model to distribution through retail locations, resulting in lower discounts, rebates, and fees than the prior year. Jaguar also launched sales of their new product for dogs in 2022, generating $167,000 in initial revenues.

Source: Company Documents
Despite strong revenue growth, Jaguar continued to report net losses in 2022 of $48.4 million, although this was an 8% improvement from net losses of $52.6 million in 2021. The losses are attributed to high operating expenses related to R&D for Jaguar's pipeline programs. Key expense items in 2022 included R&D expenses of $17.6 million, sales and marketing expenses of $8.8 million, and G&A expenses of $17.9 million.
Analyst Coverage

Jaguar Health is followed by seasoned analysts. This sell-side coverage provides important visibility and insights on Jaguar Health to the institutional investment community.

Source: Company Documents
A Deep and Seasoned Leadership Team

Jaguar Health has assembled an experienced leadership team with decades of combined expertise across R&D, development, manufacturing, business development, commercialization, legal, and financial operations.
The management team is led by Lisa Conte, the company's founder, president, and CEO, who has over 30 years of experience. Other key executives include Pravin Chaturvedi, Ph.D., the company’s Chief Scientific Officer and Chair of the Scientific Advisory Board, and Chief Medical Officer Dr. Darlene Horton, who has over 25 years of experience. This seasoned leadership team provides Jaguar Health with the strategic vision and operational capabilities to advance the company's pipeline of novel plant-based solutions.
SEC Filings
Financials
Risks & Disclosures

This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.
Jaguar Health, Inc. (the “Company”) has reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.
Information and opinions presented in the Company Presentation are provided by the Company, and b2iDigital makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment.
Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.
A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.
Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.
b2i digital or its related entities may own securities of the Company.
The Company is a client of b2i Digital. The Company agreed to pay b2i Digital no greater than $100,000 in cash for 12 months of digital marketing consulting and investor awareness services.
This communication includes forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks, uncertainties and other factors. The Company urges readers to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this communion. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this communication.
SEE THE FULL IN DEPTH STORY
The Jaguar Health management and investor relations team are available to talk to current and potential investors. They're happy to answer your questions and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
• Directly hear the Jaguar Health story
• Ask your questions
• Submit the form below, and someone will get in touch with you as soon as possible
Note: Company management or its representative can only discuss and disclose information that is already available in the public domain. They will do their best to clarify such information to the extent permitted by securities law and industry regulations.


